PRRT2 and uveal melanoma: Based on this preclinical data, we hypothesized that concurrent PKC and PI3K inhibition would lead to improved clinical outcomes when compared with PKC inhibition alone, and initiated this phase Ib, multi-center, open-label clinical trial to evaluate the clinical safety and tolerability, preliminary efficacy, pharmacokinetics, and pharmacodynamics of the combination of sotrastaurin and alpelisib in patients with advanced uveal melanoma.